Our Partners

Our Partners

Through a history of successful collaborations, Santen has built global alliances with venture businesses, universities, research centers, and other pharmaceutical companies. Each partnership continues to bring us closer toward our mission in meeting the needs of ophthalmic patients worldwide.
The following examples illustrate several of our recent successful alliances with our partners.

Our Partners

  • Aug. 2016
    InnFocus, Inc.

    Santen completed the acquisition of InnFocus, Inc., developer of the InnFocus MicroShunt®, glaucoma implant device.

  • Mar. 2016

    Santen and ONO entered into an exclusive license agreement whereby Santen will develop and commercialize ONO-9054, an FP/EP3 dual agonist for the treatment for glaucoma and ocular hypertension developed by ONO, on a worldwide basis.

  • Aug. 2015
    Ayumi Pharmaceutical Corporation

    Santen announced the completion of the transfer of anti-rheumatic pharmaceuticals business to Ayumi Pharmaceutical Corporation.

  • May. 2014
    Merck & Co., Inc., Kenilworth, N.J., U.S.A.

    Santen and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (Merck, known as MSD outside of the United States and Canada) signed an agreement for the purchase of ophthalmology products.

  • Apr. 2014
    Akorn Inc./Oak Pharmaceuticals, Inc.

    Santen and Oak Pharmaceuticals, Inc., a subsidiary of Akorn, Inc. entered into a license agreement for sales and marketing of ZIOPTAN® in the US market.

  • Mar. 2014
    TRACON Pharmaceuticals, Inc.

    Santen and TRACON Pharmaceuticals, Inc. entered into a license agreement for the development of TRC105 (anti-endoglin antibody) in ophthalmology.

  • Sep. 2012
    Eisai Co., Ltd.

    Santen and Eisai Co., Ltd. entered into an option agreement for the rights of evaluation and first negotiation for Eisai-owned compounds in the field of ophthalmology.

  • May. 2012
    Bayer Yakuhin, Ltd.

    Santen and Bayer Yakuhin, Ltd. concluded an agreement of co-promotion of EYLEA® (aflibercept intravitreal injection) in Japan.

  • Oct. 2011
    Ube Industries, Ltd.

    Santen and Ube Industries, Ltd. entered into a collaboration to develop and commercialize Ube's EP2 agonist compound for glaucoma treatment.

  • Oct. 2011
    Novagali Pharma S.A.

    Santen completed the acquisition of a controlling interest in Novagali Pharma S.A. (currently known as Santen S.A.S.)

  • Feb. 2011
    Nippon Boehringer Ingelheim Co., Ltd.

    Santen and Nippon Boehringer Ingelheim Co., Ltd. entered into an agreement to develop and commercialize epinastine eye drops (trademark: ALESION® ) for allergic conjunctivitis in Japan.